Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Krazati (adagrasib) is an oral, targeted inhibitor of the KRAS G12C mutant protein, developed for tumors driven by this specific genetic alteration, now manufactured by Bristol Myers Squibb following its 2024 acquisition of Mirati Therapeutics.
Krazati is FDA-approved for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. It is also FDA-approved, combined with cetuximab, for KRAS G12C-mutated metastatic colorectal cancer previously treated with chemotherapy.
Adagrasib selectively and irreversibly binds to the mutated KRAS G12C protein, locking it in an inactive state and blocking the downstream signaling that drives tumor growth.
The recommended dose is 600 mg orally twice daily, taken with or without food, until disease progression or unacceptable toxicity, as determined by the treating oncologist.
Krazati requires monitoring for several important safety considerations.
Obtain ECG and monitor electrolytes before starting and during treatment. Withhold, reduce dose, or permanently discontinue based on severity of QT prolongation.
Drug-induced liver injury and hepatitis have been reported. Monitor liver function tests before starting and monthly for the first 3 months of treatment, or as clinically indicated.
Serious GI problems, including bleeding, blockage, swelling, and narrowing, have occurred. Monitor for abdominal pain, nausea, or changes in bowel habits.
Monitor for new or worsening respiratory symptoms.
Krazati can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Krazati (adagrasib) is now manufactured by Bristol Myers Squibb, following its 2024 acquisition of Mirati Therapeutics, the drug's original developer.
Import of Krazati through a Named Patient Program requires a valid prescription from the treating oncologist, confirmation of KRAS G12C mutation status via an FDA-approved test, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Krazati directly from Bristol Myers Squibb's authorized supply chain to ensure product authenticity and regulatory compliance.
Krazati is sourced through verified, GDP-compliant channels from Bristol Myers Squibb's authorized supply chain to ensure authenticity and quality.
Krazati tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F), protected from moisture.
Once sourced, Krazati is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Krazati through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading oncology centers in Mumbai support KRAS G12C mutation testing and treatment coordination for Krazati access.
Delhi's major cancer hospitals assist patients with molecular testing and prescription support for Krazati.
Bangalore's oncology network offers access to KRAS testing and treatment planning for eligible patients.
Chennai-based specialists coordinate Krazati access alongside comprehensive lung and colorectal cancer care.
Hyderabad's cancer care institutions support patients pursuing Krazati therapy following confirmed KRAS G12C mutation status.
Kolkata's oncology centers help coordinate documentation and treatment access for Krazati.
Pune-based oncologists assist with KRAS mutation testing and Krazati treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Krazati.
Kochi's oncology units assist patients with the documentation needed for Krazati access.
Chandigarh's cancer care centers support Krazati treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Krazati access process.
Lucknow-based cancer centers assist patients pursuing Krazati therapy.
Bhubaneswar's oncology institutions support access to Krazati for eligible patients.
Guwahati's specialists help coordinate Krazati access for patients across the Northeast.
Patients in other cities across India can also access Krazati through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
